Teva to Sell $6.75 Billion in Stock to Buy Allergan Unit, Rimsa

Teva Pharmaceutical Industries Ltd. is selling about $6.75 billion worth of ordinary and preferred shares to fund its takeover of Allergan Plc’s generic-drug business as well as other acquisition-related expenses.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.